Nitin Jain

24.5k citations

478 papers · 10.3k · 1 hit paper · h-index 50

Impact in

Hematology top 0.1%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
Genetics top 0.1%
- Chronic Lymphocytic Leukemia Research

Papers in

Genetics 255
- Chronic Lymphocytic Leukemia Research 230
- Myeloproliferative Neoplasms: Diagnosis and Treatment 23
Hematology 209
- Chronic Myeloid Leukemia Treatments 134
- Acute Myeloid Leukemia Research 86

Co-authors: Hagop M. Kantarjian (251 shared papers)William G. Wierda (141 shared papers)Elias Jabbour (221 shared papers)Farhad Ravandi (193 shared papers)Naval Daver (96 shared papers)Guillermo Garcia‐Manero (149 shared papers)Jörge E. Cortes (106 shared papers)Marina Konopleva (133 shared papers)
Journals: Blood (194 papers)Journal of Clinical Oncology (44 papers)American Journal of Hematology (28 papers)Cancer (28 papers)Blood Advances (12 papers)
Partner nations: United States India Israel

In The Last Decade

Nitin Jain

433 papers receiving 10.1k citations

Nitin Jain's Hit Papers

align trajectories log scale

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities 2017 · 1.7k citations

Peers

Countries citing papers authored by Nitin Jain

Since Specialization

Citations

This map shows the geographic impact of Nitin Jain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nitin Jain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nitin Jain more than expected).

Fields of papers citing papers by Nitin Jain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nitin Jain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nitin Jain. The network helps show where Nitin Jain may publish in the future.

Co-authors

The 25 scholars most cited alongside Nitin Jain, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Nitin Jain Line = papers co-authored together Nitin Jain links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 478 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Chimeric antigen receptor T-cell therapy — assessment and management of toxicities Nature Reviews Clinical Oncology ·Sattva S. Neelapu, Sudhakar Tummala, Partow Kebriaei, William G. Wierda, Cristina Gutiérrez, Frederick L. Locke, Krishna V. Komanduri, Yi Lin, Nitin Jain, Naval Daver, Jason R. Westin, Alison Gulbis, Monica Loghin, John de Groot, Sherry Adkins, Suzanne E. Davis, Katayoun Rezvani, Patrick Hwu, Elizabeth J. Shpall Hit paper breakdown →	2017	1707
2	Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies American Journal of Hematology ·Courtney D. DiNardo, Caitlin R. Rausch, Christopher B. Benton, Tapan M. Kadia, Nitin Jain, Naveen Pemmaraju, Naval Daver, Wendy Covert, Kayleigh Marx, Morgan Mace, Elias Jabbour, Jörge E. Cortes, Guillermo Garcia‐Manero, Farhad Ravandi, Kapil N. Bhalla, Hagop M. Kantarjian, Marina Konopleva	2017	302
3	Local-pooled-error test for identifying differentially expressed genes with a small number of replicated microarrays Bioinformatics ·Nitin Jain, Jayant Thatte, Thomas J. Braciale, Klaus Ley, Michael J. O’Connell, Jae K. Lee	2003	262
4	Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib Blood ·Preetesh Jain, Michael J. Keating, William G. Wierda, Zeev Estrov, Alessandra Ferrajoli, Nitin Jain, Binsah George, Danelle F. James, Hagop M. Kantarjian, Jan A. Burger, Susan O’Brien	2015	243
5	Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype Blood ·Nitin Jain, Audrey L. Lamb, Susan O’Brien, Farhad Ravandi, Marina Konopleva, Elias Jabbour, Zhuang Zuo, Jeffrey L. Jorgensen, Pei Lin, Sherry Pierce, Deborah Thomas, Michael Rytting, Gautam Borthakur, Tapan M. Kadia, Jörge E. Cortes, Hagop M. Kantarjian, Joseph D. Khoury	2016	236
6	Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies Blood ·Ian W. Flinn, Susan O’Brien, Brad S. Kahl, Manish R. Patel, Yasuhiro Oki, Francine F. Foss, Pierluigi Porcu, Jeffrey A. Jones, Jan A. Burger, Nitin Jain, Virginia Kelly, Kerstin Allen, Mark Douglas, Jennifer Sweeney, Patrick Kelly, Steven M. Horwitz	2017	190
7	Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis Blood ·Fábio Pires de Souza Santos, Hagop M. Kantarjian, Nitin Jain, Taghi Manshouri, Deborah A. Thomas, Guillermo Garcia‐Manero, Debra Kennedy, Zeev Estrov, Jörge E. Cortes, Srđan Verstovšek	2009	187
8	In Vivo Genotoxicity Assessment of Titanium Dioxide Nanoparticles by Allium cepa Root Tip Assay at High Exposure Concentrations PLoS ONE ·Sunandan Pakrashi, Nitin Jain, Swayamprava Dalai, Jerobin Jayakumar, Prathna Thanjavur Chandrasekaran, Ashok M. Raichur, Natarajan Chandrasekaran, Amitava Mukherjee	2014	171
9	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study The Lancet Haematology ·Elias Jabbour, Nicholas J. Short, Farhad Ravandi, Xuelin Huang, Naval Daver, Courtney D. DiNardo, Marina Konopleva, Naveen Pemmaraju, William G. Wierda, Guillermo Garcia‐Manero, Koji Sasaki, Jörge E. Cortes, Rebecca Garris, Joseph D. Khoury, Jeffrey L. Jorgensen, Nitin Jain, Joie Alvarez, Susan O’Brien, Hagop M. Kantarjian	2018	168
10	Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimens Cancer ·Philip A. Thompson, Susan O’Brien, William G. Wierda, Alessandra Ferrajoli, Francesco C. Stingo, (unknown), Jan A. Burger, Zeev Estrov, Nitin Jain, Hagop M. Kantarjian, Michael J. Keating	2015	159
11	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience Journal of Hematology & Oncology ·Kamal Chamoun, Hagop M. Kantarjian, Rami Atallah, Graciela Nogueras González, Ghayas C. Issa, Mary Beth Rios, Guillermo Garcia‐Manero, Gautam Borthakur, Farhad Ravandi, Nitin Jain, Naval Daver, Marina Konopleva, Courtney D. DiNardo, Tapan M. Kadia, Naveen Pemmaraju, Elias Jabbour, Jörge E. Cortes	2019	147
12	Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis Cancer ·Koji Sasaki, Elias Jabbour, Farhad Ravandi, Nicholas J. Short, Deborah A. Thomas, Guillermo Garcia‐Manero, Naval Daver, Tapan M. Kadia, Marina Konopleva, Nitin Jain, Ghayas C. Issa, Vicki Jeanis, Haim G. Moore, Rebecca Garris, Naveen Pemmaraju, Jörge E. Cortes, Susan O’Brien, Hagop M. Kantarjian	2016	141
13	Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia Clinical Lymphoma Myeloma & Leukemia ·Rita Assi, Hagop M. Kantarjian, Nicholas J. Short, Naval Daver, Koichi Takahashi, Guillermo Garcia‐Manero, Courtney D. DiNardo, Jan A. Burger, Jörge E. Cortes, Nitin Jain, William G. Wierda, S Chamoun, Marina Konopleva, Elias Jabbour	2017	123
14	Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial The Lancet Haematology ·Tapan M. Kadia, Patrick K. Reville, Gautam Borthakur, Musa Yılmaz, Steven M. Kornblau, Yesid Alvarado, Courtney D. DiNardo, Naval Daver, Nitin Jain, Naveen Pemmaraju, Nicholas J. Short, Sa A. Wang, Rebecca S. Tidwell, Rabiul Islam, Marina Konopleva, Guillermo Garcia‐Manero, Farhad Ravandi, Hagop M. Kantarjian	2021	109
15	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' Nature Reviews Clinical Oncology ·Sattva S. Neelapu, Sudhakar Tummala, Partow Kebriaei, William G. Wierda, Frederick L. Locke, Yi Lin, Nitin Jain, Naval Daver, Alison Gulbis, Sherry Adkins, Katayoun Rezvani, Patrick Hwu, Elizabeth J. Shpall	2018	108
16	Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL Blood ·Paolo Strati, Michael J. Keating, Susan O’Brien, Jan A. Burger, Alessandra Ferrajoli, Nitin Jain, Francesco Paolo Tambaro, Zeev Estrov, Jeffrey L. Jorgensen, Pramoda Challagundla, Stefan Faderl, William G. Wierda	2014	105
17	Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia Blood ·Lorenzo Falchi, Michael J. Keating, Edith M. Marom, Mylene T. Truong, Ellen Schlette, Rachel L. Sargent, Long Trinh, Xuemei Wang, Susan Smith, Nitin Jain, Zeev Estrov, Susan O’Brien, William G. Wierda, Susan Lerner, Alessandra Ferrajoli	2014	101
18	Region-specific radiotherapy and neuropsychological outcomes in adult survivors of childhood CNS malignancies Neuro-Oncology ·Gregory T. Armstrong, Nitin Jain, Wanqing Liu, T.E. Merchant, Marilyn Stovall, Deo Kumar Srivastava, James G. Gurney, Roger J. Packer, Leslie L. Robison, Kevin R. Krull	2010	101
19	TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow American Journal of Hematology ·Khaled Alayed, Keyur P. Patel, Sergej Konoplev, Rajesh Singh, Mark J. Routbort, Neelima Reddy, Naveen Pemmaraju, (unknown), Abdulaziz Al Shaikh, Tariq N. Aladily, Nitin Jain, Rajyalakshmi Luthra, L. Jeffrey Medeiros, Joseph D. Khoury	2013	99
20	Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia The Journal of Immunology ·Qingsong Yin, Mariela Sivina, Harlan Robins, Erik Yusko, Marissa Vignali, Susan O’Brien, Michael J. Keating, Alessandra Ferrajoli, Zeev Estrov, Nitin Jain, William G. Wierda, Jan A. Burger	2017	90

About Nitin Jain

Nitin Jain is a scholar working on Genetics, Hematology, Public Health, Environmental and Occupational Health, Pathology and Forensic Medicine and Molecular Biology, having authored 478 papers that have together received 10.3k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (230 papers), Acute Lymphoblastic Leukemia research (160 papers), Chronic Myeloid Leukemia Treatments (134 papers), Lymphoma Diagnosis and Treatment (90 papers), Acute Myeloid Leukemia Research (86 papers), CAR-T cell therapy research (52 papers), Immunodeficiency and Autoimmune Disorders (36 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (23 papers). The work is most often cited by research in Hematology (3.3k citations), Genetics (3.0k citations), Oncology (3.7k citations), Pathology and Forensic Medicine (2.0k citations) and Public Health, Environmental and Occupational Health (2.2k citations). Nitin Jain has collaborated with scholars based in United States, India and Israel. Frequent co-authors include Hagop M. Kantarjian, William G. Wierda, Elias Jabbour, Farhad Ravandi, Naval Daver, Guillermo Garcia‐Manero, Jörge E. Cortes, Marina Konopleva, Zeev Estrov and Alessandra Ferrajoli. Their work appears in journals such as Blood, Journal of Clinical Oncology, American Journal of Hematology, Cancer and Blood Advances.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Nitin Jain

Impact in

Papers in i

In The Last Decade

Nitin Jain

Nitin Jain's Hit Papers

Peers

Countries citing papers authored by Nitin Jain

Fields of papers citing papers by Nitin Jain

All Works

About Nitin Jain

Explore authors with similar magnitude of impact

Papers in